Exendin-(9–39) Is an Inverse Agonist of the Murine Glucagon-Like Peptide-1 Receptor: Implications for Basal Intracellular Cyclic Adenosine 3′,5′-Monophosphate Levels and β-Cell Glucose Competence**This work was supported by Grant 31-46958.96 from the Swiss National Science Foundation (to B.T.).
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The effect of exendin-(9–39), a described antagonist of the glucagon-like peptide-1 (GLP-1) receptor, was evaluated on the formation of cAMP- and glucose-stimulated insulin secretion (GSIS) by the conditionally immortalized murine βTC-Tet cells. These cells have a basal intracellular cAMP level that can be increased by GLP-1 with an EC50 of approximately 1 nm and can be decreased dose dependently by exendin-(9–39). This latter effect was receptor dependent, as aβ -cell line not expressing the GLP-1 receptor was not affected by exendin-(9–39). It was also not due to the endogenous production of GLP-1, because this effect was observed in the absence of detectable preproglucagon messenger RNA levels and radioimmunoassayable GLP-1. Importantly, GSIS was shown to be sensitive to this basal level of cAMP, as perifusion of βTC-Tet cells in the presence of exendin-(9–39) strongly reduced insulin secretion. This reduction of GSIS, however, was observed only with growth-arrested, not proliferating, βTC-Tet cells; it was also seen with nontransformed mouse β-cells perifused in similar conditions. These data therefore demonstrated that 1) exendin-(9–39) is an inverse agonist of the murine GLP-1 receptor; 2) the decreased basal cAMP levels induced by this peptide inhibit the secretory response of βTC-Tet cells and mouse pancreatic islets to glucose; 3) as this effect was observed only with growth-arrested cells, this indicates that the mechanism by which cAMP leads to potentiation of insulin secretion is different in proliferating and growth-arrested cells; and 4) the presence of the GLP-1 receptor, even in the absence of bound peptide, is important for maintaining elevated intracellular cAMP levels and, therefore, the glucose competence of theβ -cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Self-citationScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 2×
“The bTCR(2) cell line was established from b-cell tumors that developed in GLP-1-R mice (14) crossed with RIP-Tag mice (15) (our manuscript in preparation).”
BackgroundResultSelf-citationMoens, K., Heimberg, H., Flamez, D., Huypens, P., Quartier, E., Ling, Z., Pipeleers, D., Gremlich, S., Thorens, B., & Schuit, F. (1996) · Diabetes · doi:10.2337/diab.45.2.257 · Cited by 250
Self-citationGut hormones and diabetes mellitus
Creutzfeldt, W., & Nauck, M. (1992) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610080206 · Cited by 176
HEINRICH, G., GROS, P., LUND, P. K., BENTLEY, R. C., & HABENER, J. F. (1984) · Endocrinology · doi:10.1210/endo-115-6-2176 · Cited by 158
Research works printed but not linked: 25
- Creutzfeld, 1983, Disturbances of the entero-insular axis., Scand J Gastroenterol [Suppl], 83, 111
- Göke, 1991, Glucagon-like peptide-1 (7–36) is a new incretin/enterogastrone candidate., Eur J Clin Invest, 21, 135, 10.1111/j.1365-2362.1991.tb01802.x · DOI
- Göke, 1988, Receptors for glucagon-like peptide-1(7–36)amide on rat insulinoma-derived cells., J Endocrinol, 116, 357, 10.1677/joe.0.1160357 · DOI · Paper page
- Usdin, 1993, Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain., Endocrinology, 133, 2861, 10.1210/endo.133.6.8243312 · DOI · Paper page
- Thorens, 1994, The gluco-incretin hormone glucagon-like peptide-1 and its β cell receptor., 357, 10.1007/978-1-4612-0241-7_15 · DOI
- Thorens, 1996, Structure and function of the glucagon-like peptide-1 receptor, 255, 10.1007/978-3-642-61150-6_16 · DOI
- Ämmälä, 1993, Calcium-independent potentiation of insulin release by cyclic AMP in single β cells., Nature, 363, 356, 10.1038/363356a0 · DOI · Paper page
- Schuit, 1985, Regulation of 3′,5′-monophosphate levels in the pancreatic B cell., Endocrinology, 117, 834, 10.1210/endo-117-3-834 · DOI · Paper page
- Gremlich, 1995, Cloning, functional expression and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor., Diabetes, 44, 1202, 10.2337/diab.44.10.1202 · DOI · Paper page
- Abrahamsen, 1995, Regulation of glucagon and glucagon-like peptide-1 receptor messenger ribonucleic acid expression in cultured rat pancreatic islets by glucose, cyclic adenosine 3′,5′-monophosphate, and glucocorticoids., Endocrinology, 136, 1572, 10.1210/endo.136.4.7534705 · doi:10.1210/endo.136.4.7534705 · Paper page
- Efrat, 1995, Conditional transformation of a pancreatic β-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene., Proc Natl Acad Sci USA, 92, 3576, 10.1073/pnas.92.8.3576 · DOI · Paper page
- Efrat, 1988, Beta-cell lines derived from tansgenic mice expressing a hybrid insulin gene-oncogene., Proc Natl Acad Sci USA, 85, 9037, 10.1073/pnas.85.23.9037 · DOI · Paper page
- Widmann, 1994, Signal transduction by the cloned glucagon-like peptide-1 receptor. Comparison with signalling by the endogenous receptors of β cell lines., Mol Pharmacol, 45, 1029, 10.1016/S0026-895X(25)10177-6 · DOI · Paper page
- Bozou, 1986, Neurotensin-mediated inhibition of cyclic AMP formation in neuroblastoma N1E115 cells: involvement of the inhibitory GTP-binding component of adenylate cyclase., Mol Pharmacol, 29, 489, 10.1016/S0026-895X(25)10277-0 · doi:10.1016/s0026-895x(25)10277-0
- Chomczynski, 1987, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction., Anal Biochem, 162, 156, 10.1016/0003-2697(87)90021-2 · DOI · Paper page
- Thorens, 1993, Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor., Diabetes, 42, 1678, 10.2337/diab.42.11.1678 · DOI · Paper page
- Kolligs, 1995, Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9–39) amide., Diabetes, 44, 16, 10.2337/diab.44.1.16 · DOI · Paper page
- Wang, 1995, Glucagon-like peptide-1 is a physiological incretin in rat., J Clin Invest, 95, 417, 10.1172/JCI117671 · DOI · Paper page
- D’Alessio, 1996, Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons., J Clin Invest, 97, 133, 10.1172/JCI118380 · DOI · Paper page
- Marie, 1996, Glucagon acts through its own receptor in the presence of functional glucagon-like peptide-1 receptors on hamster insulinoma., Endocrinology, 137, 4108, 10.1210/endo.137.10.8828464 · DOI
- Samama, 1994, Negative antagonists promote an inactive conformation of theβ 2-adrenergic receptor., Mol Pharmacol, 45, 390, 10.1016/S0026-895X(25)10009-6 · DOI · Paper page
- Chidiac, 1994, Inverse agonist activity of the β-adrenergic receptor., Mol Pharmacol, 45, 490, 10.1016/S0026-895X(25)10022-9 · DOI · Paper page
- Costa, 1989, Antagonists with negative intrinsic activity at the δ opioid receptors coupled to GTP-binding proteins., Proc Natl Acad Sci USA, 86, 7321, 10.1073/pnas.86.19.7321 · DOI · Paper page
- Milligan, 1995, Inverse agonism: pharmacological curiosity or potential therapeutic strategy?, Trends Pharmacol Sci, 16, 10, 10.1016/S0165-6147(00)88963-4 · DOI · Paper page
- Milano, 1995, Enhanced myocardial function in transgenic mice overexpressing theβ 2-adrenergic receptor, Science, 264, 582, 10.1126/science.8160017 · DOI · Paper page
Cited by
Seifert, R., & Wenzel-Seifert, K. (2002) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-002-0588-0 · Cited by 637
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Discovery, characterization, and clinical development of the glucagon-like peptides
Drucker, D. J., Habener, J. F., & Holst, J. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci97233 · Cited by 418
Self-citationGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Self-citation
Metadata
- Authors
- Serre, V., Dolci, W., Schaerer, E., Scrocchi, L., Drucker, D., Efrat, S., & Thorens, B.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 1998-11-01
- Volume
- 139
- Issue
- 11
- Pages
- 4448-4454
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2152557643
- Cited by
- 110
- References
- 6
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exendin-(9–39) Is an Inverse Agonist of the Murine Glucagon-Like Peptide-1 Receptor: Implications for Basal Intracellular Cyclic Adenosine 3′,5′-Monophosphate Levels and β-Cell Glucose Competence**This work was supported by Grant 31-46958.96 from the Swiss National Science Foundation (to B.T.). https://app.cochat.ai/papers/10.1210/endo.139.11.6295
- The paper
- Serre, V., Dolci, W., Schaerer, E., Scrocchi, L., Drucker, D., Efrat, S., & Thorens, B. (1998). Exendin-(9–39) Is an Inverse Agonist of the Murine Glucagon-Like Peptide-1 Receptor: Implications for Basal Intracellular Cyclic Adenosine 3′,5′-Monophosphate Levels and β-Cell Glucose Competence**This work was supported by Grant 31-46958.96 from the Swiss National Science Foundation (to B.T.). Endocrinology. https://doi.org/10.1210/endo.139.11.6295
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.